LexDanaLexDanabeta
Inventor

Andrew A. Young

Inventor
San Diego, CA, US

Overview

64→
Patents
1993–2020
Patent span
Human necessities
Primary field (CPC A)

Patents· 64 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Kprimary
A61KPreparations for medical, dental or toiletry purposes37%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations34%
C07KPeptides19%
C07CAcyclic or carbocyclic compounds2%
C07DHeterocyclic compounds2%
A61MDevices for introducing media into, or onto, the body1%
G01NInvestigating or analysing materials by determining their chemical or physical properties1%
A61FFilters implantable into blood vessels1%
G09GArrangements or circuits for control of indicating devices using static means to present variable information1%
H10DInorganic electric semiconductor devices1%
PatentTitleYear
10,835,580Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug202010,555,950Bile acid recycling inhibitors for treatment of obesity and diabetes202010,501,517Glucagon-receptor selective polypeptides and methods of use thereof201910,251,880Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions201910,188,646Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions201910,028,952Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof20189,345,715'Methods of treating diabetes or obesity using bile acids, bile salts, and mimics thereof'20169,339,480'Bile acid recycling inhibitors for treatment of obesity and diabetes'20169,133,260'GIP analog and hybrid polypeptides with selectable properties'20158,951,962'Modified exendins and exendin agonists'20158,895,498'GIP and exendin hybrid polypeptides'20148,759,291'Methods of treatment using exendin peptides or GLP-1 peptides'20148,497,240'DPP-IV resistant GIP hybrid polypeptides with selectable properties'20138,445,647'Modified exendins and exendin agonists'20138,404,637'GIP analog and hybrid polypeptides with selectable properties'20138,389,477'Amylin and amylin agonists for treating psychiatric diseases and disorders'20138,366,650'Biliary/pancreatic shunt device and method for treatment of metabolic and other diseases'20138,318,663'Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent'20128,288,338'Exendin and exendin agonists for eating disorders'20128,273,713'Methods of treating obesity using PYY[3-36]'20128,263,545'GIP analog and hybrid polypeptides with selectable properties'20128,168,233'Treatment of pancreatitis with amylin'20128,057,822'Modified exendins and exendin agonists'20118,026,210'Exendins and exendin agonist analogs to regulate gastrointestinal motility'20117,960,341'Methods and compositions for treating polycystic ovary syndrome'20117,928,065'Methods of treatment using exendin peptides or GLP-1 peptides'20117,928,060'Amylin family polypeptide-6 (AFP-6) analogs and methods of making and using them'20117,906,146'Lyophilized formulations of exendins and exendin agonist analogs'20117,741,269'Exendins and exendin agonists for weight reduction and obesity'20107,700,549'Exendin agonist analogs to treat diabetes'20107,691,963'Exendins and exendin agonists modified with polyamino acids'20107,683,030'Methods of treating diabetes with albumin-conjugated exendin peptides'20107,671,023'Amylin agonist for treating depression, anxiety disorder and schizophrenia'20107,608,692'Exendins and exendin agonists modified with albumin'20097,521,423'Exendin pharmaceutical compositions'20097,442,680'Inotropic and diuretic effects of GLP-1 and GLP-1 agonists'20087,419,952'Use of exendins and agonists thereof to treat diabetes'20087,407,934'Methods for regulating postprandial blood glucose'20087,407,932'Methods for glucagon suppression using modified exendins'20087,399,489'Exendin analog formulations'20087,297,761'Pharmaceutical compositions containing exendins'20077,153,825'Methods for glucagon suppression using modified exendins'20067,138,375'Use of exendins and agonists thereof for lowering plasma lipid'20067,115,569'Exendins, exendin agonists, and methods for their use'20067,105,490'Methods and compositions for treating polycystic ovary syndrome'20067,101,853'Method for treating or preventing gastritis using amylin or amylin agonists'20066,924,264'Modified exendins and exendin agonists'20056,902,744'Exendin agonist formulations and methods of administration thereof'20056,872,700'Methods for glucagon suppression'20056,858,576'Methods for regulating gastrointestinal motility'20056,703,359'Inotropic and diuretic effects of exendin and GLP-1'20046,608,029'Methods for regulating gastrointestinal motility'20036,602,694'Uncoupling protein 4 (UCP-4)'20036,114,304'Methods for regulating gastrointestinal motility'20006,048,514'Amylin activity assays'20005,814,600'Method and composition for treatment of insulin requiring mammals'19985,739,106'Appetite regulating compositions'19985,677,279'Methods and compositions for treating pain with amylin or agonists thereof'19975,656,590'Treatment of anorexia and related states'19975,527,771'Methods and Compositions for treatment of diabetes mellitus, hypoglycemia & other conditions'19965,508,260'Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions'19965,376,638'Methods for treating renin-related disorders with amylin antagonists'19945,321,008'Methods and compositions for treatment of diabetes mellitus, hypoglycemia, and other conditions'19945,234,906'Hyperglycemic compositions'1993

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

1993–2012Patents assigned to AMYLIN PHARMACEUTICALS INC (43)· patent assignee history
1993–2015Based in San Diego, CA, US· patent location history
2005–2012Based in La Jolla, CA, US· patent location history
2006–2013Based in Rancho Santa Fe, CA, US· patent location history
2011–2019Patents assigned to YOUNG ANDREW A (14)· patent assignee history
2012–2015Patents assigned to AMYLIN PHARMACEUTICALS LLC (10)· patent assignee history
2012–2020Patents assigned to SATIOGEN PHARMACEUTICALS INC (8)· patent assignee history
2012–2020Based in Chapel Hill, NC, US· patent location history
2012–2019Based in Research Triangle Park, NC, US· patent location history
2013–2015Patents assigned to ASTRAZENECA PHARMACEUTICALS LP (7)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees
AssigneePatentsSpan
AMYLIN PHARMACEUTICALS INC431993–2012
YOUNG ANDREW Aself142011–2019
AMYLIN PHARMACEUTICALS LLC102012–2015
SATIOGEN PHARMACEUTICALS INC82012–2020
ASTRAZENECA PHARMACEUTICALS LP72013–2015
Locations
LocationPatentsSpan
San Diego, California, US221993–2015
Rancho Santa Fe, California, US132006–2013
La Jolla, California, US102005–2012
Chapel Hill, NC, US82012–2020
Research Triangle Park, NC, US52012–2019